{"name":"NexImmune","slug":"neximmune","ticker":"NEXI","exchange":"NASDAQ","domain":"neximmune.com","description":"NexImmune is a biotechnology company focused on the development of immunotherapies for cancer and other diseases. The company's lead product candidate, NEXI-001, is a personalized neoantigen-based immunotherapy for the treatment of solid tumors. NexImmune is also developing NEXI-002, a vaccine candidate for the treatment of COVID-19. The company is positioned as a leader in the field of immunotherapy and nanotechnology.","hq":"Gaithersburg, MD","founded":0,"employees":"","ceo":"John Trainer","sector":"Immunotherapy / Nanotechnology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":19282230,"netIncome":-32344393,"cash":3202452,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"NexImmune Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"NexImmune reported its financial results for the fourth quarter and full year 2023, including revenue of $1.4 million and a net loss of $24.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"NexImmune Announces Collaboration with National Cancer Institute","summary":"NexImmune announced a collaboration with the National Cancer Institute to develop a personalized neoantigen-based immunotherapy for the treatment of solid tumors.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"NexImmune Announces Initiation of Phase 1 Clinical Trial for NEXI-002","summary":"NexImmune announced the initiation of a Phase 1 clinical trial for its COVID-19 vaccine candidate, NEXI-002.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbWVtSWxBNWtxeU15UHItdG9vbnpra3hVejdINTJUSThTWWt6dzdDMVFkUVZ6MVBKVGxWUUV1cUJ6dWJxRTlTUjR6Mks5NUdhVVRGX2lWOEFsOXZYVnRIeGdycXRYMXZkRzFOdmZYX0RkQVhrb3BIZmZORHN4SUxRa21BZm5fVUY4YTJJdW8tYTVremYwUzFackVCT1k2ekctUmdpcUlIU0pBNFA2NTdBU2dJVWsteEgtYnVSZFZUekg?oc=5","date":"2026-02-08","type":"pipeline","source":"AD HOC NEWS","summary":"NexImmune Inc Is Exploding Online – But Is NEXI Stock a Hidden Gem or a Total Trap? - AD HOC NEWS","headline":"NexImmune Inc Is Exploding Online – But Is NEXI Stock a Hidden Gem or a Total Trap?","sentiment":"neutral"},{"date":"2024-08-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcDdJQkU0eXFCNUZwY19KRVVVOGFJN0pITHRwdC0td2tXQm1zVDBhNzNDLVNUTHdJcUVtSEo2Sy1aZUtvb09ZSDZ1VDdCeVV2V2FSbmFibWVSVl9EVGIzcGJnM3NpVEw3N1FfVG5TaUJPNUFMa3NzNUZMSWd2VnRERHJwa2VTVFJDZWV6dkRjc2dyX1AyUmFLU21uWWxxZEdrUmx1cWdkeUMtWDQ?oc=5","date":"2024-08-15","type":"regulatory","source":"Investing.com","summary":"NexImmune shareholders approve company dissolution - Investing.com","headline":"NexImmune shareholders approve company dissolution","sentiment":"positive"},{"date":"2024-08-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-08-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-08-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-07-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-06-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-05-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1FdTBVY1ZQWnV1SXFJM2RfbC11a0tLNWxvTlBFUUxleVpHQ052VzVocWUxZGZFbXV0cWlvWEdmUEYyTkJuOV9nbGM2QjIzSUZ4Zmc?oc=5","date":"2021-05-14","type":"pipeline","source":"Yahoo Finance Singapore","summary":"NexImmune, Inc. (NEXI) stock price, news, quote and history - Yahoo Finance Singapore","headline":"NexImmune, Inc. (NEXI) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1PWmI1WU50UUxYdTJZeFFDYzk2dXRic09TRXI1RFotNWJKb2x4bFdrbDNnQ0FSN2t4NUh5RkpDb1FRRUVCWXpRVHBxR0FHMzdxRGc?oc=5","date":"2021-03-01","type":"pipeline","source":"Yahoo! Finance Canada","summary":"NexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"NexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaHp1NDdKeEd1REw2ckwycldsTjJxMy1XdkdfcUFDVFpYU1UxS2VzRVBVLXFqV2RqLTVLOERubE9NMTRBS29rTy1RUW1CclN2ajBKREt5QnAwZWhsdmVGNWVOMC1QYzYwVU1iQVd4WGtmenVSR25oTUIyLXdFckpwd0s4ekxaWG8ycFU5R3NuMExoSkVMWjJ5M0pYbThXaGFmMjRFT1BoQ2w?oc=5","date":"2021-02-19","type":"pipeline","source":"The Business Journals","summary":"Gaithersburg’s NexImmune secures $126.5M from IPO. Here’s its plan for the proceeds. - The Business Journals","headline":"Gaithersburg’s NexImmune secures $126.5M from IPO. Here’s its plan for the proceeds.","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immunotherapy","Nanotechnology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":19282230,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-32344393,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3202452,"cashHistory":[],"totalAssets":8593949,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}